Abstract
Recent developments in the rapidly advancing area of neuroprotection and neuroregeneration necessitated the need to gather over 50 of the world’s leading experts under the umbrella of the Global College of Neuroprotection and Neuroregeneration (GCNN) in its 7th Annual Meeting in Stockholm, Sweden. In this meeting, top policy-makers, together with world leaders in pharmaceutical industries, discussed the urgent need to develop new pharmaceuticals, as well as using a combination of existing ones, to treat CNS disorders in order to improve the current status of healthcare. In addition, nanobiotechnologists proposed the use of a new formulation of drugs using nanotechnologies for enhanced drug delivery to the brain for better therapeutic efficacy of the neuroprotective agents. The deliberations in this meeting provide new perspectives on the molecular and cellular mechanisms of neuroprotection and neuroregeneration that could be utilized to improve the existing healthcare for the benefit of mankind.
Financial & competing interests disclosure
The authors’ own research described here was supported by grants from the Swedish Medical Research Council (nr 2710); Göran Gustafsson Foundation, Stockholm, Sweden; Astra-Zeneca, Mölndal, Sweden; Acure Pharma, Uppsala, Sweden and Ever NeuroPharma, Unterach, Austria; European office of Aerospace Research & Development (EOARD), London office, UK; Wright Patterson Air Force Base (WPAFB), Dayton, OH, USA; US FDA, National Centre for Toxicological Research (NCTR), Jefferson, USA; Uppsala University (UU), Sweden; Department of Biotechnology, Ministry of Science & Technology, Government of India, New Delhi, India; Medical Research Council, New Delhi, India; Alexander von Humboldt Foundation, Bonn, Germany. The authors have no conflict of interest with any funding organization mentioned above. The views expressed in this article are solely those of the authors and in no way represent official positions of any granting authority or government organizations listed above. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.